These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

501 related items for PubMed ID: 22115327

  • 21. The infectious profiles of anti-tumor necrosis factor agents in a Thai population: a retrospective study a the university-based hospital.
    Suwannalai P, Auethavekiat P, Udomsubpayakul U, Janvitayanujit S.
    Int J Rheum Dis; 2009 Jul; 12(2):118-24. PubMed ID: 20374328
    [Abstract] [Full Text] [Related]

  • 22. Medicare coverage of tumor necrosis factor alpha inhibitors as an influence on physicians' prescribing behavior.
    DeWitt EM, Glick HA, Albert DA, Joffe MM, Wolfe F.
    Arch Intern Med; 2006 Jan 09; 166(1):57-63. PubMed ID: 16401811
    [Abstract] [Full Text] [Related]

  • 23. Changing patterns of tumor necrosis factor inhibitor use in 9074 patients with rheumatoid arthritis.
    Yazici Y, Krasnokutsky S, Barnes JP, Hines PL, Wang J, Rosenblatt L.
    J Rheumatol; 2009 May 09; 36(5):907-13. PubMed ID: 19332636
    [Abstract] [Full Text] [Related]

  • 24. A Retrospective Cohort Study Comparing Utilization and Costs of Biologic Therapies and JAK Inhibitor Therapy Across Four Common Inflammatory Indications in Adult US Managed Care Patients.
    Chastek B, White J, Van Voorhis D, Tang D, Stolshek BS.
    Adv Ther; 2016 Apr 09; 33(4):626-42. PubMed ID: 26970958
    [Abstract] [Full Text] [Related]

  • 25. Disability outcomes and dose escalation with etanercept, adalimumab, and infliximab in rheumatoid arthritis patients: a US-based retrospective comparative effectiveness study.
    Schabert VF, Bruce B, Ferrufino CF, Globe DR, Harrison DJ, Lingala B, Fries JF.
    Curr Med Res Opin; 2012 Apr 09; 28(4):569-80. PubMed ID: 22236091
    [Abstract] [Full Text] [Related]

  • 26. The use of adalimumab, etanercept, golimumab and infliximab in rheumatic pathologies: variation between label dosage and real-world use.
    Martinez-Cutillas J, Alerany-Pardo C, Borrás-Blasco J, Broto-Sumalla A, Burgos-SanJosé A, Climent-Bolta C, Escudero-Vilaplana V, Fernández-Fuente MA, Ferrit-Martin M, Gómez-Germá P, Martínez-Sesmero JM, Mayorga-Pérez J, Menchén-Viso B, Merino-Alonso J, Polache-Vengud J, Sánchez-Guerrero A.
    Expert Rev Pharmacoecon Outcomes Res; 2015 Apr 09; 15(5):851-8. PubMed ID: 25972066
    [Abstract] [Full Text] [Related]

  • 27. Impact of a Patient Support Program on Patient Adherence to Adalimumab and Direct Medical Costs in Crohn's Disease, Ulcerative Colitis, Rheumatoid Arthritis, Psoriasis, Psoriatic Arthritis, and Ankylosing Spondylitis.
    Rubin DT, Mittal M, Davis M, Johnson S, Chao J, Skup M.
    J Manag Care Spec Pharm; 2017 Aug 09; 23(8):859-867. PubMed ID: 28737994
    [Abstract] [Full Text] [Related]

  • 28. Dosing patterns and costs of tumor necrosis factor inhibitor use for rheumatoid arthritis.
    Harrison DJ, Huang X, Globe D.
    Am J Health Syst Pharm; 2010 Aug 09; 67(15):1281-7. PubMed ID: 20651319
    [Abstract] [Full Text] [Related]

  • 29. Paradoxical adverse events of anti-tumour necrosis factor therapy for spondyloarthropathies: a retrospective study.
    Fouache D, Goëb V, Massy-Guillemant N, Avenel G, Bacquet-Deschryver H, Kozyreff-Meurice M, Ménard JF, Muraine M, Savoye G, Le Loët X, Tharasse C, Vittecoq O.
    Rheumatology (Oxford); 2009 Jul 09; 48(7):761-4. PubMed ID: 19395543
    [Abstract] [Full Text] [Related]

  • 30. Do tumor necrosis factor inhibitors cause uveitis? A registry-based study.
    Lim LL, Fraunfelder FW, Rosenbaum JT.
    Arthritis Rheum; 2007 Oct 09; 56(10):3248-52. PubMed ID: 17907169
    [Abstract] [Full Text] [Related]

  • 31. Biologic disease-modifying drug treatment patterns and associated costs for patients with rheumatoid Arthritis.
    McBride S, Sarsour K, White LA, Nelson DR, Chawla AJ, Johnston JA.
    J Rheumatol; 2011 Oct 09; 38(10):2141-9. PubMed ID: 21844154
    [Abstract] [Full Text] [Related]

  • 32. Infliximab drug and infusion costs among patients with Crohn's disease in a commercially-insured setting.
    Ollendorf DA, Lidsky L.
    Am J Ther; 2006 Oct 09; 13(6):502-6. PubMed ID: 17122530
    [Abstract] [Full Text] [Related]

  • 33. Comparisons of affinities, avidities, and complement activation of adalimumab, infliximab, and etanercept in binding to soluble and membrane tumor necrosis factor.
    Kaymakcalan Z, Sakorafas P, Bose S, Scesney S, Xiong L, Hanzatian DK, Salfeld J, Sasso EH.
    Clin Immunol; 2009 May 09; 131(2):308-16. PubMed ID: 19188093
    [Abstract] [Full Text] [Related]

  • 34. New onset of uveitis during anti-tumor necrosis factor treatment for rheumatic diseases.
    Wendling D, Paccou J, Berthelot JM, Flipo RM, Guillaume-Czitrom S, Prati C, Dernis E, Direz G, Ferrazzi V, Ristori JM, CRI.
    Semin Arthritis Rheum; 2011 Dec 09; 41(3):503-10. PubMed ID: 21862108
    [Abstract] [Full Text] [Related]

  • 35. Cost per patient-year in response using a claims-based algorithm for the 2 years following biologic initiation in patients with rheumatoid arthritis.
    Bonafede M, Johnson BH, Princic N, Shah N, Harrison DJ.
    J Med Econ; 2015 May 09; 18(5):376-89. PubMed ID: 25530318
    [Abstract] [Full Text] [Related]

  • 36. Anti-tumor necrosis factor therapy: 6 year experience of a single center in northern Israel and possible impact of health policy on results.
    Braun-Moscovici Y, Markovits D, Rozin A, Toledano K, Nahir AM, Balbir-Gurman A.
    Isr Med Assoc J; 2008 Apr 09; 10(4):277-81. PubMed ID: 18548981
    [Abstract] [Full Text] [Related]

  • 37. Impact of leflunomide versus biologic agents on the costs of care for rheumatoid arthritis in a managed care population.
    Ollendorf DA, Peterson AN, Doyle J, Huse DM.
    Am J Manag Care; 2002 May 09; 8(7 Suppl):S203-13. PubMed ID: 12022236
    [Abstract] [Full Text] [Related]

  • 38. Cost of tumor necrosis factor blockers per patient with rheumatoid arthritis in a multistate Medicaid population.
    Bonafede M, Joseph GJ, Shah N, Princic N, Harrison DJ.
    Clinicoecon Outcomes Res; 2014 May 09; 6():381-8. PubMed ID: 25246804
    [Abstract] [Full Text] [Related]

  • 39. Anti-TNF-alpha treatment: a possible promoter in endogenous uveitis? observational report on six patients: occurrence of uveitis following etanercept treatment.
    Kakkassery V, Mergler S, Pleyer U.
    Curr Eye Res; 2010 Aug 09; 35(8):751-6. PubMed ID: 20673052
    [Abstract] [Full Text] [Related]

  • 40. Persistence and dose escalation of tumor necrosis factor inhibitors in US veterans with rheumatoid arthritis.
    Cannon GW, DuVall SL, Haroldsen CL, Caplan L, Curtis JR, Michaud K, Mikuls TR, Reimold A, Collier DH, Harrison DJ, Joseph GJ, Sauer BC.
    J Rheumatol; 2014 Oct 09; 41(10):1935-43. PubMed ID: 25128516
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 26.